Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Type 2

This study is currently recruiting participants.

Verified by University Hospital Tuebingen, March 2008

Sponsors and Collaborators:	University Hospital Tuebingen German Research Foundation
Information provided by:	University Hospital Tuebingen
ClinicalTrials.gov Identifier:	NCT00638209

Purpose

The purpose of the study is to investigate whether insulin sensitivity of the human brain correlates with insulin sensitivity of the liver.

Condition	Intervention
Human Physiology of Energy Homeostasis	Drug: Human insulin Drug: Saline

MedlinePlus related topics: Diabetes

Drug Information available for: Insulin

Study Type:	Interventional
Study Design:	Basic Science, Randomized, Single Blind (Subject), Placebo Control, Crossover Assignment
Official Title:	Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Typ 2

Further study details as provided by University Hospital Tuebingen:

Primary Outcome Measures:

Insulin effect on cortical function (spectral analysis) [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment:	42
Study Start Date:	February 2008
Estimated Primary Completion Date:	May 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
I: Active Comparator	Drug: Human insulin
P: Placebo Comparator	Drug: Saline

Eligibility

Criteria

Inclusion Criteria:

Age 18-70 Risk factor(s) for type 2 diabetes (e.g. overweight, family history of diabetes)

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00638209

Contacts

Contact: Andreas Fritsche, MD

+49 7071 29 80590

Locations

Germany
University Hospital Tuebingen	Recruiting
Tuebingen, Germany, 72076
Contact: Andreas Fritsche +49 7071 29 80590 andreas.fritsche@med.uni-tuebingen.de
University Hospital Tuebingen, Internal Medicine IV	Recruiting
Tuebingen, Germany, 72076

Sponsors and Collaborators

University Hospital Tuebingen

German Research Foundation

More Information

Responsible Party:	University Hospital Tuebingen, Internal Medicine IV ( Prof. Andreas Fritsche )
Study ID Numbers:	MEG-KFO-2, EudraCT 2006-004734-32, KFO-114
Study First Received:	March 12, 2008
Last Updated:	March 18, 2008
ClinicalTrials.gov Identifier:	NCT00638209
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Study placed in the following topic categories:

Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases

Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders
Insulin

Additional relevant MeSH terms:

Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009